Skip to main content

Table 4 Comparison between therapeutic response group and no-response group

From: Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

 

No-response group

Response group

P-value

Recipient sex, male

8/11

25/50

.171

Recipient age

43.6 ± 15.4

47.1 ± 11.7

.389

Donor sex, male

5/11

27/48

.517

Donor age

37.1 ± 9.0

37.1 ± 12.3

.994

Hematologic malignancy

  

.976

 AML

3

14

 

 ALL

4

16

 

 CML

0

1

 

 NHL

0

2

 

 MDS

4

17

 

Donor type

  

.167

 Unrelated

3

25

 

 Sibling

5

20

 

 FMT

3

5

 

HLA

  

.717

 full-match

7

36

 

 mismatch

4

14

 

Stem cell source

  

1.000

 PB

10

41

 

 BM

1

7

 

 Cord

0

2

 

Time from HSCT to BOS diagnosis, days

407.0 (272.0–1533.0)

466.0 (274.3–833.3)

.910

Acute GVHD

8/11

31/50

.731

Chronic GVHD (except lung)

 Skin

6/11

25/50

0.785

 Oral

7/11

35/50

0.726

 Eyes

9/11

27/50

0.106

 Liver

2/11

8/50

1.000

 Joint

0/11

3/50

1.000

Maximal score of chronic GVHD (except lung)a

1 (1–2)

1 (1–2)

0.227

Systemic steroid

8/11

25/50

.171

Steroid dose, mg (equivalent dose of prednisolone)

12.5 (4.4–16.3)

2.5 (0.0–15.0)

.151

Tacrolimus

3/11

15/50

1.000

Cyclosporin

1/11

8/50

.683

Mycophenolate mofetil

5/11

13/50

.275

total CAT score, enroll

10.5 (6.8–16.0)

16.0 (10.0–20.0)

.083

  1. aEach organ was scored as 0, 1, 2 or 3 based on the degree of functional impairment. Data represent the mean ± SD, median (IQR) or n. AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myelogenous leukemia, NHL non-Hodgkin lymphoma, MDS myelodysplastic syndrome, FMT familial-mismatched/haploidentical transplantation, HLA human leukocyte antigen, PB peripheral blood, BM bone marrow, HSCT hematopoietic stem cell transplantation, BOS bronchiolitis obliterans syndrome, GVHD graft-versus-host disease, CAT COPD assessment test